NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 130 filers reported holding NURIX THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $121,000 | +611.8% | 5,790 | +397.4% | 0.00% | – |
| Q1 2024 | $17,000 | -89.0% | 1,164 | -92.2% | 0.00% | – |
| Q4 2023 | $154,000 | +140.6% | 14,923 | +84.1% | 0.00% | – |
| Q3 2023 | $64,000 | +10.3% | 8,107 | +39.7% | 0.00% | – |
| Q2 2023 | $58,000 | +141.7% | 5,804 | +112.9% | 0.00% | – |
| Q1 2023 | $24,000 | -68.8% | 2,726 | -61.5% | 0.00% | – |
| Q4 2022 | $77,000 | +670.0% | 7,083 | +816.3% | 0.00% | – |
| Q3 2022 | $10,000 | +150.0% | 773 | +119.0% | 0.00% | – |
| Q2 2022 | $4,000 | -85.7% | 353 | -82.6% | 0.00% | – |
| Q1 2022 | $28,000 | -86.3% | 2,027 | -71.4% | 0.00% | – |
| Q4 2021 | $205,000 | +2177.8% | 7,095 | +2196.1% | 0.00% | – |
| Q3 2021 | $9,000 | +125.0% | 309 | +111.6% | 0.00% | – |
| Q2 2021 | $4,000 | -94.1% | 146 | -93.3% | 0.00% | – |
| Q1 2021 | $68,000 | +423.1% | 2,190 | +440.7% | 0.00% | – |
| Q4 2020 | $13,000 | +333.3% | 405 | +305.0% | 0.00% | – |
| Q3 2020 | $3,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP III, LLC | 3,422,549 | $90,800,000 | 15.85% |
| Ponoi II Management, LLC | 686,274 | $18,207,000 | 14.76% |
| Ponoi Management, LLC | 686,274 | $18,207,000 | 10.12% |
| Foresite Capital Management V, LLC | 451,522 | $11,979,000 | 4.71% |
| Foresite Capital Management IV, LLC | 1,205,798 | $31,990,000 | 4.32% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $34,073,000 | 2.23% |
| EcoR1 Capital, LLC | 1,967,950 | $52,210,000 | 1.95% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $15,155,000 | 1.93% |
| DAFNA Capital Management LLC | 306,320 | $8,127,000 | 1.70% |
| Euclidean Capital LLC | 154,426 | $4,097,000 | 1.33% |